Andrew T Metcalf

USPTO Granted Patents = 29 (Patent Applications = 6)

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 11)

Average Co-Inventor Count = 12.6

ph-index = 5

Forward Citations = 90(Granted Patents)

Location History:

Boulder, CO (US) (2017 - 2024)
Erie, CO (US) (2022 - 2024)
Indianapolis, IN (US) (2024)

Company Filing History:

Eli Lilly and Company

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

29 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12209086 - FGFR3 inhibitor compounds (2025-01-28),

2. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),

3. 11964988 - Fused heterocyclic compounds as RET kinase inhibitors (2024-04-23),

4. 11878976 - FGFR3 inhibitor compounds (2024-01-23),

5. 11807651 - Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2023-11-07),

6. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),

7. 11634409 - Compounds for the treatment of BRAF-associated diseases and disorders (2023-04-25),

8. 11603374 - Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors (2023-03-14),

9. 11524963 - Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors (2022-12-13),

10. 11472802 - Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors (2022-10-18),

11. 11414404 - Compounds for the treatment of BRAF-associated diseases and disorders (2022-08-16),

12. 11247990 - Bicyclic fused pyridine compounds as inhibitors of TAM kinases (2022-02-15),

13. 11098064 - Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrile (2021-08-24),

14. 10953005 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2021-03-23),

15. 10881652 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2021-01-05),

Title: Andrew T Metcalf: A Visionary Inventor Shaping the Future of Medicine

Introduction: Andrew T Metcalf, a brilliant inventor based in Boulder, CO, is renowned for his unwavering dedication to innovation and his relentless pursuit of pushing the boundaries of what is possible in the world of inventions.

Latest Patents: Andrew T Metcalf's recent patents include groundbreaking discoveries in the field of medicine. One of his latest inventions involves FGFR3 inhibitor compounds, which are utilized in the treatment of various conditions such as systemic sclerosis, fibrosis, achondroplasia, and cancer. Another notable patent is a process for the preparation of a compound with significant pharmaceutical applications.

Career Highlights: With an impressive portfolio of 26 patents, Andrew T Metcalf has established himself as a true trailblazer in the realm of inventions. Throughout his career, he has demonstrated unparalleled expertise in translating innovative ideas into tangible solutions that have the potential to revolutionize the healthcare industry.

Collaborations: Andrew T Metcalf has collaborated with leading companies such as Array Biopharma Inc. and Genentech, Inc., where he has worked alongside talented individuals like David A Moreno and Adam Wade Cook. These collaborative efforts have not only enriched his work but have also contributed to the development of groundbreaking technologies.

Conclusion: Andrew T Metcalf's passion for innovation, coupled with his exceptional skills as an inventor, sets him apart as a true pioneer in the world of inventions. His relentless drive to explore new frontiers and his commitment to making a positive impact on society solidify his position as a visionary shaping the future of medicine.

This text is generated by artificial intelligence and may not be accurate.